Ahead of The Bell: (NASDAQ: INBS) Tops Our Watchlist Today Following its Recent FDA Milestone

*Sponsored Krypton Street Announces Intelligent Bio Solutions Inc. (NASDAQ: INBS) As Its Next Potential Breakout Idea… And Here’s Why… A recent report from Ladenburg Thalmann lists a $12 target for (INBS), suggesting over 733% potential upside. With fewer than 4.2M shares in the float, (INBS) has potential for significant swings if demand begins to shift. (INBS) submitted a 510(k) premarket notification to the FDA, paving the way for U.S. market entry in 2025. (INBS) serves over 400 active accounts across 19 countries, with a U.S. launch poised to enter one of the largest testing markets globally. Fiscal year 2024 saw 148% revenue growth for (INBS), demonstrating its ability to scale successfully. Substance misuse costs the U.S. economy $400B annually; (INBS) targets this $14.9B market with its fingerprint-based testing platform. Keep reading to see why it may be time to consider adding Intelligent Bio Solutions Inc. (NASDAQ: INBS) to your radar… January 28, 2025 Dear Reader, We have all eyes on (INBS) ahead of the bell this morning. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is topping our watchlist today following its FDA milestone. While many industries garner headlines for their breakthroughs, some of the most transformative progress happens quietly, reshaping the world without the spotlight. Progress is fueled by fresh ideas, and nowhere is this more apparent than in the testing industry.  For years, outdated methods have created barriers with slow, invasive, and cumbersome processes.  A revolutionary solution is now transforming the landscape, offering faster, non-invasive, and highly accurate results.  At the forefront of this change is a company reshaping the future of medical technology. Leading this transformation is a company redefining the future of medical technology. Intelligent Bio Solutions Inc. (NASDAQ: INBS) has developed cutting-edge solutions that are not only faster and more precise but also accessible and non-invasive.  Their work is paving the way for a smarter, more efficient future across industries worldwide. The potential hasn’t gone unnoticed.  On January 24, 2025, Jeffrey S. Cohen, Director of Research and Managing Director of Equity Research in Healthcare & Medical Technologies at Ladenburg Thalmann Co. Inc.—a firm with NYSE membership since 1879—published a report mentioning Intelligent Bio Solutions Inc. (NASDAQ: INBS). Setting a $12 target, which suggests potential upside of over 733% from yesterday’s $1.44 open. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is now trending above key moving averages including: 5-Day: 1.434 20-Day: 1.398 And with its 50-Day Moving Average at 1.4783,  100-Day at 1.5664, and 200-Day at 1.77, we’re keeping a very close eye on (INBS). Especially since there’s less than 4.2M shares listed in the (INBS) float. With a limited float like this there’s the potential for significant swings if demand begins to shift. Recent Developments Princebuild Partnership: Transitioning to Fingerprint Sweat-Based Screening Intelligent Bio Solutions Inc. (NASDAQ: INBS) recently partnered with Princebuild, a leading construction firm with operations spanning six key divisions across the UK. Princebuild has transitioned from saliva testing to (INBS)’s Intelligent Fingerprinting Dr-ug Screening System, integrating the technology at its seven UK sites.  This strategic move underscores the efficiency, accuracy, and respect for employee privacy that the fingerprint-based system offers. "By adopting Intelligent Bio Solutions’ fingerprint sweat-based system, we have transformed our approach to workplace testing," said Cheryl Browne, Human Resources Support Manager at Princebuild.  "We wanted a method that ensured safety in our workplace without feeling like we were policing our employees' lifestyles. The simplicity and efficiency of this solution align with our company values." Princebuild joins other prominent construction companies like Mount Anvil, Hayfield Homes, and PJ Hegarty & Sons UK Ltd., which rely on Intelligent Bio Solutions Inc. (NASDAQ: INBS)’s technology to ensure employee fitness for duty while fostering safer workplaces. With over 400 active accounts in 19 countries, (INBS)’s fingerprint-based system is already making a difference across industries, including construction, manufacturing, transport, treatment, and law enforcement.  The partnership with Princebuild highlights the system’s scalability and ability to adapt to the needs of diverse workplaces. FDA Submission Marks Milestone for Intelligent Bio Solutions Inc. (NASDAQ: INBS)’s U.S. Expansion Plan In December 2024, INBS achieved a significant milestone by submitting its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Screening System.  This marks a crucial step in the Company’s plan to enter the U.S. market in 2025. The submission included robust performance data, including a method comparison study demonstrating 94.1% accuracy and a Pharmacokinetic (PK) study confirming the reliability of fingerprint sweat as a sample matrix for detection.  These findings underscore the system’s capacity to deliver rapid, non-invasive, and accurate testing solutions to meet growing demand. "The submission of our 510(k) application to the FDA is an impactful moment for all of us at Intelligent Bio Solutions," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions Inc. (NASDAQ: INBS). "We are excited about our planned entry into the U.S. market, the opps for growth, and the transformational impact that we believe we will have in the dr-ug screening market with our innovative technology." With existing adoption in international markets, the Intelligent Fingerprinting Screening System is already recognized for delivering substantial cost savings, operational efficiencies, and rapid results.  Its expansion into the U.S.—one of the largest dr-ug screening markets globally—is expected to drive revenue growth, enhance market share, and establish strategic partnerships across industries such as construction, mining, logistics, and law enforcement. A New Standard: Intelligent Fingerprinting Screening System At the heart of (INBS)’s groundbreaking innovation is the Intelligent Fingerprinting Screening System, a technology poised to revolutionize portable testing.  Leveraging fingerprint sweat analysis, this hygienic, non-invasive system is designed to screen for the recent use of substances like opiates, cocaine, methamphetamine, and cannabis.  Sample collection takes mere seconds, and results are available in under ten minutes—a game-changer for industries where time and accuracy are paramount. Broader Applications: Beyond the Workplace While its immediate focus is workplace testing, this system’s potential applications extend far beyond.  The ability to analyze fingerprint sweat efficiently and reliably opens doors to broader fields, including healthcare, law enforcement, and treatment programs.  By eliminating the logistical challenges associated with traditional methods like urine and saliva testing, (INBS) is making testing more convenient and less intrusive—all while maintaining uncompromising accuracy. A Vital Tool for Safety-Critical Industries (INBS)’s technology is particularly valuable for employers in safety-critical industries such as construction, manufacturing, and transport.  The simplicity and speed of the testing process mean that employees can be screened without disrupting operations.  This efficiency ensures workplace safety while minimizing downtime—a crucial benefit in high-stakes environments. Proven Success in Global Markets Intelligent Bio Solutions already serves over 400 active accounts outside the U.S., with their customers spanning diverse sectors, including: Construction, manufacturing, and engineering firms requiring on-site testing for worker safety. Transport and logistics companies where safety compliance is paramount. Treatment organizations seeking reliable and non-invasive monitoring tools. Coroners, who benefit from the hygienic and straightforward nature of fingerprint-based screening. This global footprint demonstrates the versatility and demand for INBS’s solutions, laying the groundwork for their U.S. launch in 2025. The Numbers Don’t Lie Behind (INBS)’s innovative solutions is a company with serious momentum. Highlights include: 148% revenue growth in fiscal year 2024, reaching $3.11M. Plans for a U.S. product launch in 2025 following the FDA 510(k) submission in late 2024. A growing customer base with 1,000+ DSR-Plus readers deployed globally. These milestones underscore (INBS)’s commitment to scaling its solutions and meeting global demand for smarter testing. Why It Matters: Addressing a Global Need Substance misuse costs the U.S. economy an estimated $400B annually, with significant impacts on workplace safety and productivity.  The dr-ug screening market, projected to reach $14.9B by 2030, is primed for disruption—and (INBS) is leading the charge with its intelligent, fingerprint-based platform.  By aligning with market demands for speed, accuracy, and convenience, (INBS) is addressing one of the most pressing challenges in workplace safety and beyond. The Road Ahead: A Vision for 2025 and Beyond As Intelligent Bio Solutions Inc. (NASDAQ: INBS) gears up for its U.S. launch in 2025, the anticipation is unmistakable.  This is a company with a forward-thinking vision, a proven track record, and the determination to redefine what’s possible in medical technology. For those seeking innovation with a purpose, (INBS) isn’t just solving problems—it’s shaping the future. 7 Reasons Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) is Topping Our Watchlist This Morning… 1. Analyst Endorsement with Bold Projections: A recent report from Ladenburg Thalmann listed a $12 target for (INBS), suggesting a potential upside of over 733% from this yesterday’s open.  2. Limited Float: With fewer than 4.2M shares in the float, (INBS) has the potential for significant movements, particularly if demand begins to shift. 3. FDA Milestone: In December 2024, (INBS) reached a critical juncture by submitting its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Screening System. This step underscores its readiness for U.S. market entry in 2025 and compliance with stringent regulatory standards. 4. Expanding Global Footprint: With more than 400 active accounts across 19 countries, (INBS) has proven international demand for its technology. The upcoming U.S. launch positions it to enter one of the largest testing markets in the world. 5. Revenue Growth: Reporting 148% revenue growth in fiscal year 2024, reaching $3.11M, (INBS) has demonstrated its ability to scale successfully and meet increasing market demand. 6. Targeting a $400B Economic Challenge: Substance misuse costs the U.S. economy an estimated $400B annually, with significant impacts on workplace safety and productivity. With the screening market projected to grow to $14.9B by 2030, (INBS)’s intelligent, fingerprint-based platform is positioned to lead this transformative space. 7. Innovative Technology: The Intelligent Fingerprinting Screening System delivers rapid, non-invasive results in under 10 minutes. Its versatility extends beyond workplaces to include applications in healthcare, law enforcement, and forensic fields—critical areas requiring reliable and efficient solutions. Don’t Overlook Intelligent Bio Solutions Inc. (NASDAQ: INBS)—Here’s Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) is advancing the frontier of medical technology with its innovative fingerprint-based screening platform. Backed by a bold $12 target from Ladenburg Thalmann, a groundbreaking FDA milestone, and 148% revenue growth in fiscal year 2024, the company is poised to make a lasting impact.  With an expanding global presence, a limited share float, and the potential to address a $400B economic challenge, (INBS) is well-positioned to lead the transformation of the screening market.  As it prepares for its U.S. launch in 2025, (INBS) continues to demonstrate the scalability, relevance, and versatility of its solutions across diverse industries. Consider taking a look at (INBS) while it’s still early. We have all eyes on (INBS) right now.  Watch for my next update on (INBS) –  it could be coming right after the bell rings. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 01/27/2025 and ending on 01/28/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, Media 1717 LLC has been paid ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/inbs/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice